PLAU and breast carcinoma: In addition to having a prognostic impact in breast cancer, uPA and PAI-1 measurements in breast cancer appear to possess therapy predictive value, especially in predicting benefit from cyclophosphamide-methotrexate-5-fluorouracil (CMF) in the adjuvant setting.